Kidney Cancer

736 posts

Kidney Cancer banner
Kidney Cancer

Kidney Cancer

@KCA_Journal

Editors-in-Chief: Primo N. Lara Jr., MD, and Peter Mulders, MD | Dedicated to expediting our understanding & improving treatments of kidney cancer

SoMeEditor: Neeraj Agarwal, MD Katılım Haziran 2017
694 Takip Edilen1.5K Takipçiler
Kidney Cancer retweetledi
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
COSMIC-313: Addition of Cabozantinib to Ipi+nivo overcomes M2-like macrophage-mediated immune suppression @AlbigesL 👇@DrChoueiri @motzermd @urotoday @kidneycan @OncoAlert #GU25 @ASCO #kidneycancer
Neeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet media
Yüksel Ürün@DrYukselUrun

COSMIC-313: Final OS Analysis @AlbigesL Cabo+Nivo+Ipi (C+N+I) maintains PFS & ORR benefits vs. Placebo+N+I in 1L IMDC intermediate/poor risk aRCC. No OS difference between arms 🧬 High M2 macrophage abundance linked to improved OS with C+N+I #GU25 @asco #kidneycancer #cancer #oncology @dryukselurun @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @tompowles1 @Uromigos @TiansterZhang @ERPlimackMD @OncBrothers

English
0
21
36
4.4K
Kidney Cancer retweetledi
Cristiane D Bergerot, PhD, FASCO
Cristiane D Bergerot, PhD, FASCO@crisbergerot·
Good morning, @ASCO #GU25! ☀️ Ready to kick off the third and final day! Starting with the poster session on RCC, penile, and testicular cancer, followed by oral abstracts, biomarkers & adjuvant therapy for RCC, trials in progress, and a case-based session (failure on immuno)
Cristiane D Bergerot, PhD, FASCO tweet mediaCristiane D Bergerot, PhD, FASCO tweet mediaCristiane D Bergerot, PhD, FASCO tweet media
English
0
6
10
2.6K
Kidney Cancer retweetledi
Jun Gong
Jun Gong@jgong15·
@katy_beckermann KEYMAKER-UO3 PhI/II #accRCC after #IO-based tx (>50% >3 prior lines) ➡️ Len/belzutifan higher ORR 47% vs Len/pembro 40% vs pembro/belzut 19% w/higher PFS for len + belzutifan (12.5 mos). OS not mature. Interesting activity for Len/belzutifan #GU25 @OncoAlert
Jun Gong tweet mediaJun Gong tweet mediaJun Gong tweet mediaJun Gong tweet media
English
0
11
13
926
Kidney Cancer retweetledi
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Congrats to @DrChoueiri @motzermd for developing one of the most effective combinations cabozantinib + nivolumab for mRCC #kidneycancer 👉Checkmate 9ER phase 3 trial👉continued strong OS benefit @tompowles1 @AlbigesL @asco #GU25 @OncoAlert @urotoday @kidneycan @KidneyCancer 👇
Neeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet media
Toni Choueiri, MD@DrChoueiri

Final #CheckMate9ER results (5+ yr FU: N+C > S in 1L #aRCC PFS HR 0.58, OS HR 0.79, ORR 55.7% vs 27.4%. No new safety signals. N+C remains a SOC for untreated aRCC. @ASCO #GU25 @motzermd @tompowles1 @MSKCancerCenter @OncoAlert

English
1
22
51
6.7K
Kidney Cancer retweetledi
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Outstanding talk and discussion on emerging treatment landscape of mRCC #kidneycancer by @TiansterZhang 👉 emphasizes the need to personalize treatment in mRCC #kidneycancer 👉next gen trials 👇@urotoday @kidneycan @OncoAlert @KidneyCancer #GU25 @ASCO @apolo_andrea
Neeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet media
Yüksel Ürün@DrYukselUrun

Eye opener discussion @TiansterZhang ASCO GU 2025: Clear Cell RCC – Beyond the Dichotomy 🔬 ccRCC is not a monolith! 🧬 Molecular complexity: VHL, PBRM1, SETD2, BAP1 📊 Transcriptomic clusters & tumor microenvironment drive heterogeneity 🚀 Precision medicine is key! #GU25 @asco #kidneycancer #cancer #oncology @DrChoueiri @dryukselurun @MikeSerzanMD @drenriquegrande @crisbergerot @reginabarcar @DRBakaloudiMD @ReneeSaliby @yekeduz_emre @neerajaiims @PGrivasMDPhD @CParkMD @OncLive @apolo_andrea @OncoBellmunt @sonpavde @MattGalsky @tompowles1 @Uromigos @kalasri3 @TiansterZhang @AndreaNecchi @ERPlimackMD @OncBrothers

English
0
21
46
4.5K
Kidney Cancer retweetledi
Sumanta K. Pal, MD, FASCO
Sumanta K. Pal, MD, FASCO@montypal·
Have been so impressed w @mzugman. After joining us at @cityofhope from @hosp_einstein, he has been prolific with multiple papers, abstracts & ISTs. He wrote the paper in @OncJournal below & offers terrific insights on this updated data from #TIVO3, pointing to durable benefits with #tivozanib particularly in the #ICI pre-treated population. @brian_rini @DrTHut @CPRT65 @elena_verzoni @Uromigos @neerajaiims @DrChoueiri @KidneyCancer @kidneycan
Miguel Zugman, MD@mzugman

1/7 Pleased to share updated OS results from the #TIVO-3 study (NCT02627963), previously presented at #ESMO24. Our analysis focused on outcomes in patients with #ccRCC who had received prior treatment with a checkpoint inhibitor (CPI) - representing 26% of the trial population.

English
0
10
21
3.3K

Keşfet

@OncoAlert @urotoday @PCF_Science @neerajaiims @huntsmancancer @InovaSchar @JAMANetworkOpen @flatironhealth